GT Biopharma

GT Biopharma EBIT Margin

The EBIT Margin (Operating Margin) of GT Biopharma (GTBP) as of Oct 22, 2026 is -502,111.11 %. In the previous year, EBIT Margin (Operating Margin) was -33,062.96 % — a change of 1,418.65% (lower).

EBIT Margin

-502,111.11 %

YoY

1,418.65%

Last updated:

EBIT Margin (Operating Margin) of GT Biopharma is 2017 -502,111.11 % . EBIT Margin (Operating Margin) of GT Biopharma was 2016 -33,062.96 % . It decreases by 1,418.65% lower compared to the previous year.

GT Biopharma's operating (EBIT) margin stands at -502,111.1%, down from -1,027.5% several years earlier.

The GT Biopharma EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2009
-24.08 USD
Jan 1, 2010
-227.00 USD
Jan 1, 2011
-151.08 USD
Jan 1, 2012
-10.27 USD
Jan 1, 2013
-2.15 USD
Jan 1, 2014
-3,927.87 USD
Jan 1, 2015
-33,062.96 USD
Jan 1, 2017
-502,111.11 USD
The GT Biopharma EBIT Margin history
YEAREBIT MarginYoY
-502,111.11 %+1,418.65%
-33,062.96 %+741.75%
-3,927.87 %+182,176.89%
-2.15 %-79.03%
-10.27 %-93.20%
-151.08 %-33.45%
-227.00 %+842.56%
-24.08 %+2,173.10%
-1.06 %+474.27%
-0.18 %-60.09%
-0.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

EBIT Margin (Operating Margin) of GT Biopharma is -502,111.11 % in 2017.

EBIT Margin (Operating Margin) of GT Biopharma changed from -33,062.96 % to -502,111.11 %, representing a 1,418.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s GT Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — GT Biopharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — GT Biopharma